An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Sponsor: AstraZeneca
Listed as NCT03699449, this PHASE2 trial focuses on Platinum-resistant Recurrent Ovarian Cancer and remains ongoing. Sponsored by AstraZeneca, it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
May 2021 — Apr 2023 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2019 — Mar 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Korean Gynecologic Oncology Group
- Samsung Genomic Institute
- Samsung Medical Center
- Seoul National University Hospital
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .